Inovio Pharmaceuticals Inc (INO)
10.16
+0.39
(+3.99%)
USD |
NASDAQ |
May 31, 16:00
10.14
-0.02
(-0.20%)
After-Hours: 20:00
Inovio Pharmaceuticals Enterprise Value: 157.64M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 157.64M |
| May 30, 2024 | 147.53M |
| May 29, 2024 | 154.53M |
| May 28, 2024 | 163.60M |
| May 24, 2024 | 179.40M |
| May 23, 2024 | 178.37M |
| May 22, 2024 | 185.88M |
| May 21, 2024 | 179.14M |
| May 20, 2024 | 182.25M |
| May 17, 2024 | 205.31M |
| May 16, 2024 | 225.78M |
| May 15, 2024 | 233.04M |
| May 14, 2024 | 190.29M |
| May 13, 2024 | 188.73M |
| May 10, 2024 | 170.33M |
| May 09, 2024 | 184.02M |
| May 08, 2024 | 179.36M |
| May 07, 2024 | 183.24M |
| May 06, 2024 | 202.16M |
| May 03, 2024 | 207.86M |
| May 02, 2024 | 205.52M |
| May 01, 2024 | 194.64M |
| April 30, 2024 | 191.02M |
| April 29, 2024 | 192.31M |
| April 26, 2024 | 168.22M |
| Date | Value |
|---|---|
| April 25, 2024 | 156.69M |
| April 24, 2024 | 157.60M |
| April 23, 2024 | 163.04M |
| April 22, 2024 | 153.97M |
| April 19, 2024 | 145.16M |
| April 18, 2024 | 158.63M |
| April 17, 2024 | 153.11M |
| April 16, 2024 | 119.57M |
| April 15, 2024 | 151.24M |
| April 12, 2024 | 152.17M |
| April 11, 2024 | 169.23M |
| April 10, 2024 | 163.39M |
| April 09, 2024 | 166.19M |
| April 08, 2024 | 159.42M |
| April 05, 2024 | 170.05M |
| April 04, 2024 | 173.67M |
| April 03, 2024 | 182.79M |
| April 02, 2024 | 184.42M |
| April 01, 2024 | 201.02M |
| March 28, 2024 | 195.86M |
| March 27, 2024 | 175.99M |
| March 26, 2024 | 160.80M |
| March 25, 2024 | 161.27M |
| March 22, 2024 | 143.04M |
| March 21, 2024 | 128.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-105.65M
Minimum
Jun 28 2023
4.820B
Maximum
Jun 29 2020
685.59M
Average
256.39M
Median
Jul 03 2019
Enterprise Value Benchmarks
| Stereotaxis Inc | 147.33M |
| Novavax Inc | 1.902B |
| Sangamo Therapeutics Inc | 61.77M |
| Vaxart Inc | 108.86M |
| Capricor Therapeutics Inc | 140.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.47M |
| Total Expenses (Quarterly) | 31.48M |
| EPS Diluted (Quarterly) | -1.31 |
| Earnings Yield | -53.94% |
| Normalized Earnings Yield | -57.64 |